

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CCL24/Eotaxin-2/MPIF-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross-reactivity with recombinant mouse CCL24/Eotaxin-2/MPIF-2 is observed and less than 5% cross-react
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human CCL24/Eotaxin-2/MPIF-2 Val27-Cys119 Accession # AAB51135
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Neutralization	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Eotaxin, also named MPIF-2 and Ckβ6, is a novel CC chemokine identified in the Human Genome Sciences, Inc. database based on the presence of the CC motif and homology with other known CC chemokines. Eotaxin-2 cDNA encodes a 119 amino acid residue precursor protein with a 26 aa residue signal peptide that is cleaved to generate a mature protein predicted to contain 93 amino acid residues with an N-glycosylation site. Although one recombinant preparation of MPIF-2/Eotaxin-2 from insect cells was reported to be glycosylated and of the predicted size (10.5 kDa), a second preparation of recombinant Eotaxin-2 prepared by a different group, also from insect cells, was shown to contain a 78 amino acid residue carboxy-terminally truncated variant of Eotaxin-2. Additional minor carboxy-terminally truncated variants with 73, 75 and 76 residues were also isolated. Compared to other CC chemokines, Eotaxin-2 exhibits 40%, 42% and 39% amino acid identity to MCP-3, MIP-1α, and Eotaxin, respectively. Eotaxin-2 mRNA is weakly expressed in activated monocytes and T lymphocytes.

Recombinant Eotaxin-2 has been shown to induce chemotaxis of eosinophils, basophils, and resting T lymphocytes but not monocytes and activated T lymphocytes. Eotaxin-2 has also been shown to suppress the colony formation by the high proliferative potential colony-forming cells which represent multipotential hematopoietic progenitors. On eosinophils, the effects of Eotaxin-2 was shown to be inhibited by an anti-CCR-3 antibody and to be cross-desensitized by Eotaxin or MCP-4, suggesting that all three CC chemokines act through CCR-3, at least on eosinophils.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.